Lupin Limited has informed the Exchange regarding a press release dated December 29, 2025, titled "Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has signed an exclusive License, Supply and Distribution agreement with China's Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly (once every two weeks) GLP-1 receptor agonist. The drug is being developed for adults with type 2 diabetes and weight management in overweight or obese individuals, and Lupin says clinical data show weight loss results comparable to or better than existing weekly GLP-1 options. Under the deal, Lupin gets exclusive rights to commercialize and distribute Bofanglutide in India, strengthening its diabetes portfolio and marking its entry into the obesity segment. The company highlighted India's large addressable market — roughly 174 million overweight adults, 50 million obese adults, and 90 million living with diabetes.
This is a positive strategic move that gives Lupin a first-mover advantage with a potential first-in-class fortnightly GLP-1 drug in India, tapping into the fast-growing obesity and diabetes segments. For shareholders, it signals portfolio expansion into a high-demand therapy area, though the financial terms of the deal were not disclosed and commercial success will depend on regulatory approval and market uptake.